Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Vistagen Therapeutics (VTGN) · oqro.io/stocks/VTGN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Vistagen Therapeutics insider trading
Have Vistagen Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Vistagen Therapeutics was filed in the last 90 days. The latest on record was on Aug 7, 2023.
How often do Vistagen Therapeutics insiders buy and sell shares?
Since 2011, Vistagen Therapeutics insiders reported 10 open-market purchases and 3 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2023.
Who is selling Vistagen Therapeutics stock?
No open-market sale by an insider of Vistagen Therapeutics (VTGN) was filed with the SEC in the last 90 days.
Do members of Congress trade VTGN?
No trade in Vistagen Therapeutics (VTGN) was disclosed by a member of Congress in the last 12 months.
When does Vistagen Therapeutics report its next results?
Vistagen Therapeutics's next results are expected on Feb 10, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
VTGN price and disclosed activity
−96.3% (−$4.29) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $4.45 on Nov 20, 2025 to $0.1636 on Nov 20, 2026 (−96.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$-1$1$2$3$4$5$6$0.1636
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in South San Francisco, Ca.
Last 12 months
−96.3%
S&P 500 +5.7% over the same dates
Market value
$7.56M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.49M shares sold short (5.4% of shares outstanding), +0.6% vs the previous count, 3.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 13, 2026.
Insiders of Vistagen Therapeutics reported 10 open-market purchases and 3 sales since 2011; purchases in 6 different years, most recently 2023.
Year
Bought
Sold
2023
$18M1×1 trade
—
2022
$171K3×3 trades
$53K1×1 trade
2021
$10K1×1 trade
$94K1×1 trade
2020
$21K1×1 trade
—
2019
$30K3×3 trades
—
2017
—1×1 trade
—
2011
—
—1×1 trade
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Late-stage clinical trials
2 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in social anxiety disorder, social anxiety disorder (sad).
3 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Funds and stakes. BVF PARTNERS L P/IL cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026). Commodore Capital LP cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026). (Vistagen Therapeutics on OQRO)
Contracts, lobbying and filings. FINRA short interest for VTGN on the settlement date of Oct 30, 2026 was 2,488,148 shares (+0.64% on the previous report), about 3.42 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Orbimed Advisors LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Vistagen Therapeutics filed a Form 8-K on Nov 13, 2026 (Item 2.02) that OQRO classes as: reported its results. The press release filed with it is titled: "Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update Advancing potential to execute"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
BVF PARTNERS L P/IL cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026).
Commodore Capital LP cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026).
Contracts, lobbying and filings
FINRA short interest for VTGN on the settlement date of Oct 30, 2026 was 2,488,148 shares (+0.64% on the previous report), about 3.42 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Orbimed Advisors LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2026, the company's proxy statement reported total compensation of $1.21M for its principal executive officer, and an average of $701K for the other named executive officers.
Company reports, price and press
Vistagen Therapeutics filed a Form 8-K on Nov 13, 2026 (Item 2.02) that OQRO classes as: reported its results.
The press release filed with it is titled: "Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update Advancing potential to execute"
Its announcing sentence reads: "Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2027 second quarter ende..."
Vistagen Therapeutics filed a Form 8-K on Oct 30, 2026 (Items 2.05, 8.01) that OQRO classes as: announced job cuts, closures or a restructuring, and reported other company news.
The company's own opening sentence of that report reads: "On October 26, 2026, Vistagen Therapeutics, Inc. (the ' Company ') implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for..."
Press coverage listed by Finnhub: "Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update" (Yahoo, Nov 13, 2026).
VTGN closed at $0.1636 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $0.1936 to $0.1636, a change of −15.5%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
From “Business Overview”, in the company's words
We are a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of non-systemic intranasal product candidates called pherines. Our broad and diverse neuroscience pipeline currently consists of five clinical-stage pherine product candidates, each with a novel mechanism of action (MOA) and positive clinical data in their targeted indication(s). Pherines specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons, and are designed to rapidly activate nose-to-brain neurocircuits believed to regulate brain areas without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits.
What the section covers (18 headings)
Business Overview
Subsidiaries
Components of Results of Operations
Sublicense and Other Revenue
Operating Expenses
Research and Development Expenses
General and Administrative Expenses
Results of Operations for the Years Ended March 31, 2026 and 2025
Liquidity and Capital Resources
Sources of Liquidity
Cash Flows
Operating Activities
Investing Activities
Financing Activities
And 4 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Jun 15, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
When insiders usually buy
Last results
Nov 13, 2026
Within the 30 days after it, until Dec 13, 2026
Next results, expected
Feb 10, 2027
Purchases after results
60%
6 of 10 insider purchases since 2016 came within 30 days after a results announcement
From Vistagen Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Vistagen Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Owners above 5%
Latest filing Nov 16, 2026
Nobody is above 5% on the latest filings: every recent filer has reported going below the line.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Off-exchange trading: 61.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (2.9% on ATS, 58.1% with other brokers), close to its 26-week average of 60.7%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: MS RPOOL (ATS-6) (18.4%), INTELLIGENT CROSS LLC (11.0%), LEVEL ATS (9.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Jun 15, 2026, compared with the one filed Jun 17, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
We may not realize the expected benefits from our workforce reduction and we may incur additional costs implementing it or other difficulties.
No longer listed (1 heading from the year before)
We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
Legal proceedings (Item 3)
Cesario et al. v. Vistagen Therapeutics, Inc. et al. (Northern District of California). On February 13, 2025, John Cesario and David Preka (the Cesario Plaintiffs) filed a civil action, pro se (i.e., acting on their own behalf rather than through an attorney), in the United States District Court for the Northern District of California (Case No. 4:25-cv-01510) (the Complaint) against the Company and its Board, certain of its executive officers, professional services and financial advisors, and industry analysts.
Source: SEC EDGAR, Form 10-K filed Jun 15, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Funds and stakes. BVF PARTNERS L P/IL cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026). Commodore Capital LP cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026). (Vistagen Therapeutics on OQRO)
Contracts, lobbying and filings. ClinicalTrials.gov shows 3 studys sponsored by the company updated in the period; the latest, "Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)" (Phase 3, status active not recruiting), was updated on May 22, 2026, with primary completion listed for 2026-04-21. FINRA short interest for VTGN on the settlement date of Oct 30, 2026 was 2,488,148 shares (+0.64% on the previous report), about 3.42 days of average volume.
Company reports, price and press. Vistagen Therapeutics filed a Form 8-K on Oct 30, 2026 (Items 2.05, 8.01) that OQRO classes as: announced job cuts, closures or a restructuring, and reported other company news. The company's own opening sentence of that report reads: "On October 26, 2026, Vistagen Therapeutics, Inc. (the ' Company ') implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for..."
Who holds it. 45 funds reported a stake in Vistagen Therapeutics in their 13F for Q2 2026. The largest by value: Commodore Capital LP (25.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (14.1% of the value reported), TWO SIGMA INVESTMENTS, LP (7.6% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
BVF PARTNERS L P/IL cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026).
Commodore Capital LP cut its VTGN stake below 5% (3.7%) (filed Nov 16, 2026).
Contracts, lobbying and filings
ClinicalTrials.gov shows 3 studys sponsored by the company updated in the period; the latest, "Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)" (Phase 3, status active not recruiting), was updated on May 22, 2026, with primary completion listed for 2026-04-21.
FINRA short interest for VTGN on the settlement date of Oct 30, 2026 was 2,488,148 shares (+0.64% on the previous report), about 3.42 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Orbimed Advisors LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2026, the company's proxy statement reported total compensation of $1.21M for its principal executive officer, and an average of $701K for the other named executive officers.
Company reports, price and press
Vistagen Therapeutics filed a Form 8-K on Oct 30, 2026 (Items 2.05, 8.01) that OQRO classes as: announced job cuts, closures or a restructuring, and reported other company news.
The company's own opening sentence of that report reads: "On October 26, 2026, Vistagen Therapeutics, Inc. (the ' Company ') implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for..."
Vistagen Therapeutics filed a Form 8-K on Oct 9, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On October 7, 2026, the Board of Directors (the ' Board ') of Vistagen Therapeutics, Inc. (the ' Company ') approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally a..."
Vistagen Therapeutics filed a Form 8-K on Aug 5, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
The company's own opening sentence of that report reads: "On August 4, 2026, Vistagen Therapeutics, Inc. (the ' Company ') received an extension notification (the ' Extension Notice ') from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (' Nasdaq ') granting the Compan..."
VTGN closed at $0.1995 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $0.2031 to $0.1995, a change of −1.8%.
Who holds it
45 funds reported a stake in Vistagen Therapeutics in their 13F for Q2 2026. The largest by value: Commodore Capital LP (25.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (14.1% of the value reported), TWO SIGMA INVESTMENTS, LP (7.6% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
On the public record for Vistagen Therapeutics over the 12 months to Nov 21, 2026: 2 clinical trials.